In the News

NanoPass’s intradermal delivery platform used in Emergex’s next generation COVID-19 vaccination study

26 January 2022

As Covid mutates, the vaccine makers are adapting too

11 December 2021

UK firm to trial T-cell Covid vaccine that could give longer immunity

15 November 2021

Covid live: Egypt starts vaccine trial; Austria to put unvaccinated people in lockdown

14 November 2021

CNBC news interview with Emergex Vaccines CEO, Professor Thomas Rademacher

14 May 2018

BioWorld: Thinking on a global scale, Emergex Vaccines using lessons from Ebola outbreak

3 May 2018

LONDON – The lessons of the Ebola epidemic have come together with a series of scientific advances, and expertise acquired over a lifetime in biotech, to inspire a novel vaccine technology that is designed to provide genus-wide protection against viral infections.

View PDF